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Background: Monomethylsilanetriol (MMST) has been used for decades as an oral silicon supplement for bone and
connective tissue health, although there are no formal data on its in vivo utilisation or safety following sustained dosing.
Methods: To investigate whether MMST contributes to the body pool of silicon and, secondly, to establish its safety
following 4 weeks’ supplementation in humans, twenty-two healthy pre-menopausal women (22–38 years) were
recruited and supplemented with MMST at the maximum daily recommended dose (10.5 mg Si/day) for 4 weeks in a
double-blind, randomised, placebo-controlled, cross-over design (i.e. 8 weeks in total). Fasting serum and urine samples
were collected at baseline and at the end of the 4-week supplementation/placebo periods for analysis of total silicon by
inductively coupled plasma optical emission spectrometry, MMST by proton nuclear magnetic resonance spectroscopy
and full serum biochemistry. Participants also reported on, by questionnaire, their health, well-being and quality of life at
0, 4 and 8 weeks.
Results: Overall, 4-weeks supplementation with MMST significantly increased total fasting Si concentrations in serum
and urine (P ≤ 0.003; paired t-test). MMST was semi-quantifiable in serum and quantifiable in urine, but only accounted
for ca. 50% and 10%, respectively, of the increased total-Si concentration. There were no reported adverse effects (i.e.
changes to health and well-being) or serum biochemical changes with MMST versus placebo.
Conclusions: Our data indicate that oral MMST is safe, is absorbed and undergoes sufficient metabolism in vivo to raise
fasting serum silicon levels, consistent with other well absorbed forms of dietary silicon (e.g. orthosilicic acid). It thus
appears to be a suitable silicon supplement.
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Inductively Coupled Plasma Optical Emission Spectrometry, Orthosilicic acidBackground
In spite of much research on dietary silicon in relation to
its role in normal bone and connective tissue health, its
proposed function [1,2], and especially its essentiality [3,4],
remains unproven in higher animals. Indeed, the case for a
functional role of dietary silicon in humans (e.g. in optimal
connective tissue health) may be best elucidated by a long-
term, prospective intervention study but, in which case, a
readily bioavailable and safe form of Si must be deter-
mined. Monomethylsilanetriol (MMST) has been an over-* Correspondence: ravin.jugdaohsingh@mrc-hnr.cam.ac.uk
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distribution, and reproduction in any mediumthe-counter Si supplement of long-standing use through-
out the world and especially in continental Europe (e.g.
France). It does not contain nano-silica particles unlike
some silicon supplements and, over which, safety concerns
have been expressed [5,6]. However, the European Safety
Authority recently advised that insufficient data currently
exist to justify the use of MMSTas an oral supplement [7].
MMST is a monomeric, organosilicon molecule [Si
(OH)3CH3] that is stable in aqueous solution at high
concentrations (~ 20 mM at room temperature; unpub-
lished data) compared to its naturally occurring inorganic
analogue (orthosilicic acid, Si(OH)4). MMST is readily
absorbed following ingestion and no adverse effects have
been reported [8-14], although no formal studies on itsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of the Si-CH3 bond occurs with bioconversion to the puta-
tive bioactive form of Si (i.e. Si(OH)3CH3 → Si(OH)3OH)
is not clear. In favour of this hypothesis is that MMST posi-
tively influences connective tissues, namely bone [8,11,12]
and blood vessels [9] in mammalian studies, in much the
same way that dietary Si does [2] and supplementation in
rats leads to increased Si levels in the connective tissues
(Jugdaohsingh et al., unpublished data). It has been pro-
posed that biological cleavage of the Si-CH3 bond in
MMST should be possible, based upon clear evidence with
other organosilicons in vivo [15-19]. The primary objective
of this study, therefore, was to gain insight into the metab-
olism of MMST and its ability, or not, to contribute to the
body pool of Si following sustained dosing at the maximum
daily recommended dose of this product, in humans.
The ‘body pool’ of Si is currently best assessed in fasting
serum samples. Following ingestion, dietary and some sup-
plemental forms of Si are relatively rapidly absorbed into
the circulation [14,20-23], and this is especially true for
MMST [10,14]. The majority is then rapidly excreted in
urine [22-24], but a minority probably undergoes tissue
loading and/or cellular metabolism [24] and sustained low
dose Si supplementation, with an inorganic source of Si,
appears to lead to a marked rise in the body pool of Si, as
reflected in fasting serum and urine Si concentrations [25].
Analysis of non-fasting serum levels, however, can lead to
falsely high results as the measured Si may include not
only that in equilibrium but also that recently absorbed
and not yet lost from the circulation. Our previous studies
show that serum Si levels fall to baseline 6 hours after in-
gestion of typical dietary doses of Si, suggesting that this,
or later, is the optimum time point for measurement
of fasting Si levels [14,20-23]. The actual time frame is
both dose- and Si species dependent but for the rapidly
absorbed MMST, at typical low doses (e.g. 3.5 mg Si
three times per day against a usual dietary background of
20–30 mg per day), post-absorptive clearance is very rapid
(a few hours; [10,14]). To be extra careful, in this study, a
minimum fasting time between last ingestion and blood or
urine sampling of 10 hours was used. A secondary objec-
tive of this study was to investigate the safety of MMST
supplementation in humans.
Subjects and methods
Subjects
Twenty-two healthy pre-menopausal females, aged between
22 and 38 years, with no history of serious illness and not
taking any medication or silicon-containing food supple-
ments, were recruited to the study by circular email from
King’s College London (UK) (Table 1). Volunteers were ex-
cluded who were pregnant and lactating, of child-bearing
age and not taking contraception, or not able to follow the
study protocol. Young women were chosen because Sisupplementation is likely to be most relevant in this popu-
lation since epidemiological data have shown a pronounced
positive association between dietary Si intakes and bone
mineral density in this group [26]. Indeed, it is hypothesised
that estradiol is required for Si to have any biological effect
[26,27]. The women were randomly assigned to coded
Placebo or MMST (silicon supplement: 10.5 mg Si/day) for
4 weeks each, in a crossover design; i.e. 11 participants took
placebo for four weeks followed by MMST for four weeks
and the remaining 11 participants took MMST for four
weeks followed by placebo for four weeks (Figure 1). An-
thropometric data (age, weight, height and BMI) were col-
lected for each participant and there were no statistical
differences in baseline parameters (see Table 1) or baseline
biochemistry (Additional file 1) between the two groups.
The study was conducted according to the guidelines
laid down in the Declaration of Helsinki and was approved
by the Research Ethics Committee of King’s College
London (UK). All participants gave signed written consent
following oral and written explanation of the study details.
Materials
Ultra-high purity (UHP) water (18 MΩ cm) was from an
Elga water purifier (Elga Ltd, High Wycombe, UK) and
2H2O (99.98%) was from Cambridge Isotopes (Andover,
MA, USA). Both were shown by ICP-OES to contain
< 5 μg/L Si. Nitric acid (65% (w/v) HNO3) was high
purity from Fluka Ltd (Gillingham, UK). The needles
(21 Gauge) and plastic syringes used for blood collection
were from Terumo Europe NV (Leuven, Belgium). Polypro-
pylene transport tubes from Sarstedt Ltd (Leicester, UK)
were washed with UHP water and air-dried (in a class J
clean room) prior to use. Serology tubes (EDTA, serum
separating tube (SST) and fluoride) were from BD (Oxford,
UK). Polypropylene Mauser bottles (2.5 L) from Aldrich
Chemical Co (Gillingham, UK) were cleaned with 10% (v/v)
HNO3 (AnalaR; BDH Ltd, UK), thoroughly rinsed with
UHP water, air dried and pre-weighed prior to use for urine
collection. For 1H-NMR analysis of MMST, all labware
(HDPE bottles, Teflon FEP syringes, glass NMR tubes) was
successively washed in dichloromethane, acetone, aqueous
detergent and UHP water so as to eliminate any silicone
residue. Pasteur pipettes (3.5 mL) used for sample transfer
were from Greiner Bio-One Limited (Stonehouse, UK).
Stock silicon ICP standard solution (9,650 mg/L Si) was
from Aldrich Chemical Co (Gillingham, UK), whereas pyri-
dine was from Sigma Aldrich Ltd (Oakville, Canada). The
MMST silicon supplement and the placebo were prepared,
packaged and supplied in a blinded fashion by the manufac-
turer, namely LLR-G5 Ltd (Castlebar, Ireland).
Study design
The study was double-blind and of crossover design
(Figure 1). All participants were supplemented with MMST
Table 1 Baseline characteristics of the subjects in the two randomised groups (MMST first followed by placebo or
placebo first followed by MMST)
MMST first 4 weeks (n=11) Placebo first 4 weeks (n=11)
Mean sd Range Mean sd Range
Age (y) 24.6 1.8 22-28 28.5 5.1 23-38
Height (m) 1.65 0.07 1.52-1.73 1.65 0.74 1.60-1.75
Weight (kg) 56.4 4.4 49-62 60.8 6.2 50-69
BMI (kg/m2) 20.76 1.12 18.5-22.5 22.44 2.27 19.5-25.6
Serum Creatinine (μmol/L) 66 7 57-78 68 10 51-85
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which is equivalent to 40% of total average daily dietary
Si intake in this population [22]) and placebo, each for
4 weeks, but the order was randomised. All data analysis
was completed and kept confidential by the authors prior
to the codes being sent by the manufacturer.
Participants attended The Gastrointestinal Laboratory
at St Thomas’ Hospital on three occasions at four-week
intervals. They fasted from 10.30 pm on the night pre-
ceding each visit until 9:30 am when their blood and
urine samples were collected. Participants were asked to
empty their bladder upon waking or, if they had not
done so, upon their arrival at The Gastrointestinal La-
boratory. Blood and urine (second void) were collected
and a quality-of-life questionnaire completed (complete
details below). The age, height, weight and body mass
index (BMI) of the participants were recorded during
the first visit (week-0) and the subjects were randomisedN= 22 
Healthy pre-menopausal women 
(age: 22-38 y)
MMST
30 mL × 3 times/d
before meals
(10.5 mg Si/d)
4 wk
30
END OF STUDY E
Randomised
Crossover
30
MMST
30 mL × 3 times/d
before meals
(10.5 mg Si/d)
4 wk
Figure 1 Study design. Flow diagram summarising the double-blind, randto receive 28 coded bottles of either the placebo or
MMST supplement, i.e. one bottle per day for 28 days
(4 weeks). The two solutions (MMST and placebo) were
identical in appearance, colour, taste, odour and pack-
aging. Participants were instructed to take 30 mL of
either MMST (3.5 mg Si) or placebo three times a day
before meals (breakfast, lunch and dinner) during the
next four weeks. To aid with compliance, a dosing cup
was provided to each participant and all solutions were
contained in 90 mL plastic bottles. At the second visit
(week-4), participants were given 28 bottles of the op-
posite solution to that given at visit-1 and instructed to
maintain the same dosing regimen until returning for
the next visit (week-8).
Blood and urine collections
Twenty mL of blood was collected from a forearm vein of
each fasted participant, and transferred for later analysisPlacebo
 mL × 3 times/d
before meals
4 wk
ND OF STUDY
Visit 1 (t=0 wk): 
Baseline fasting bloods & urine
Questionnaires
Visit 2 (t=4 wk): 
Fasting bloods & urine
Questionnaires
Visit 3 (t=8 wk): 
Fasting bloods & urine
Questionnaires
Sample/data collection
Placebo
 mL × 3 times/d
before meals
4 wk
omised, placebo controlled cross-over study design.
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SST (biochemistry) tubes; and d) a Si- and anticoagulant-
free polypropylene tube. The latter sample was left to clot
at room temperature for one hour before being cen-
trifuged at 2,000 g and 4°C for 10 min; the separated
serum was then transferred to a second Si-free polypro-
pylene tube and stored at −20°C for later determination of
total-Si and MMSTcontent.
Second-void urine was also collected. Prior to each visit,
participants emptied their bladder upon waking (first-void
urine) and then only consumed, ad libitum, UHP water up
to the time they collected their second-void urine (between
08.30-09.30 a.m.) in a polypropylene Mauser bottle. Ten
mL of the fresh, homogenous urine was then transferred
into a 25 mL polypropylene bottle and diluted with 10 mL
nitric acid (0.7%, ultra-high-purity) to prevent precipitation
of minerals during storage at 4°C. A subset of these urine
samples was analysed for MMSTas detailed below.
Analyses
Total-silicon
Total-Si analysis was carried out by inductively coupled
plasma optical emission spectrometry (Jobin-Yvon JY24;
Instruments SA, Lonjumeau, France) with a V-groove
nebuliser and a Scott-type double-pass spray chamber at
251.611 nm. Sample flow rate was 1 mL/min and peak
profiles were assessed as before [20,28]. Standards and
samples were analysed at least in duplicate.
Serum samples were thawed at room temperature and
diluted four-fold with dilute high-purity nitric acid; i.e.
3 mL of 0.26% (v/v) nitric acid was added to 1 mL serum.
Sample-based standards were prepared by pooling 1 mL
of each diluted serum sample and then spiking aliquots
with varying amounts of Si (0, 50, 100 or 200 μg/L), using
a working stock silicon solution of 101.60 mg/L that was
prepared from silicon ICP standard. The sample ‘blank’
was 0.26% (v/v) nitric acid.
Urine samples (diluted 1:1 with 0.7% (v/v) nitric acid)
were incubated overnight in an oven at 40°C prior to ana-
lysis, to re-solubilise any precipitates formed during stor-
age. One mL of each diluted urine sample was pooled
and, again, aliquots of this pooled sample were spiked with
0, 5, 10 or 20 mg/L Si to make the ‘pooled sample-based
standards’.
MMST by 1H-NMR
A subset of the fasting serum (n=9) and urine samples
(n=10) following MMST supplementation were analysed
by 1H-NMR, firstly to determine whether MMST could
be detected and secondly to investigate whether it was
converted/metabolised to OSA. Samples were chosen
based on the likelihood of detecting MMST, that is, those
which exhibited large increases in total-Si concentration
compared to baseline. Baseline serum (n=3) and urine(n=5) samples which contained high total-Si were used as
controls, along with placebo samples (n=4 serum and
urine) which exhibited apparent increases in total-Si com-
pared to baseline.
Approximately 0.6 g sample and 0.2 g 2H2O (con-
taining 0.025 wt% pyridine as an internal quantitative
nuclear magnetic resonance (QNMR) reference) were
precisely weighed into 5 mm O.D. NMR tubes. A series
of QNMR calibration standards were similarly prepared
using dilute stock solutions of MMST (Dow Corning
777) and potassium hydrogen phthalate (Sigma Aldrich).
One-dimensional solvent-supressed 1H NMR spectra
were acquired at 25°C on a Varian Unity Inova 500 spec-
trometer, using 90° observe pulses (375 for urine, 700 for
serum) and a 4 s recycle period.
Blood biochemistry
The safety of MMST was assessed by changes in serum
biochemistry following supplementation with MMST
and placebo. Fasting blood samples collected at all three
time points were sent to the Clinical Biochemistry La-
boratory at St Thomas' Hospital for clinical assessment
of renal function, liver function, lipid profile, thyroid
stimulating hormones (TSH), C reactive protein (CRP) and
other blood analytes to determine the safety of the MMST
and placebo solutions. Samples were analysed on a clinical
chemistry analyser (Roche Modular Analytics (Roche Diag-
nostics Ltd, Switzerland), P module for routine chemistry
and E module for hormones/tumour markers etc.).
Health, wellness and quality of life
As a further check on the safety of the MMST and placebo
solutions, at each visit the participants completed a ques-
tionnaire in which they self-assessed their well-being and
quality of life. The questionnaires were created specifically
for this study (see Additional file 1) but were adapted from
typical such questionnaires in the art (see: www.donaldep
stein.com/pdf/newlongitudinal.pdf for example).
Statistical analysis
Results are expressed as means ± 1 standard deviation
(SD), unless otherwise stated. Of the 22 recruited partic-
ipants, complete serum datasets (total-Si concentrations)
were only available for 14 participants (i.e. data for all
three collections: week-0 (“baseline”), week-4 and week-8),
allowing paired analyses, while 18 participants had com-
plete urine datasets. Of the eight participants with incom-
plete serum dataset: one did not have values for all three
time points (but did have urine data); five had no baseline
values; one subject had no values at baseline and week 4,
while another participant had no value at week 4. Reasons
were: unable to collect or provide a blood sample, Si
concentration in the diluted baseline serum sample for
analysis was below the limit of quantification (44 μg/L), or
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Figure 2 Fasting serum and urinary silicon levels before and after
supplementation with MMST and placebo. (A) Fasting serum total-Si
concentrations before supplementation (Baseline: n = 14) or following 4
weeks supplementation with organic silicon (MMST: n = 14) or 4 weeks
of placebo (Placebo: n =14). Data is shown as box-plots, where the
horizontal lines indicate the 5th, 25th, 50th (or median), 75th and 95th
percentiles, the open square shows the mean and the crosses the
minimum and maximum values. Total-Si concentrations were
significantly higher following supplementation with MMST compared to
Baseline (P = 0.0002; paired t-test) or Placebo (P = 0.003; paired t-test).
No effect of the order in receiving the solutions (i.e. MMST before or after
placebo) was observed. (B) Fasting urine total-Si concentrations before
supplementation (Baseline: n = 18) or following 4 weeks
supplementation with organic silicon (MMST: n = 18) or 4 weeks of
placebo (Placebo: n =18). Total-Si concentration was significantly higher
following supplementation with MMST compared to Baseline (P = 0.008;
paired t-test) or Placebo (P = 0.007; paired t-test). No effect of the order
in receiving the solutions (i.e. MMST before or after placebo)
was observed.
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serum Si concentration after 4 weeks supplementation
with MMST. Of the four subjects with incomplete urine
dataset: two subjects had no values for all three time
points; one subject did not have a value for week 4; and
one subject did not have a value for week 8. Reasons were:
unable to provide a sample, urine infection, or subject did
not fast. Differences between groups were analysed with a
paired (samples) t-test. P<0.05 was considered to be sig-
nificant. To correct for multiplicity of testing, a Bonferroni
Correction was applied to the P value. No previous human
data exist for sample size (power) calculation.
Results
Metabolism of MMST
Fasting total serum silicon
For the 14 participants with complete serum datasets, four
weeks of supplementation with MMST led to a markedly
significant increase in fasting serum silicon concentration
(mean 272 μg/L) compared to baseline (mean 173 μg/L:
P = 0.0002) or to placebo (mean 191 μg/L: P = 0.003)
(Figure 2A). There was no effect of treatment order
(i.e. MMST before placebo or placebo before MMST; data
not shown).
Fasting total urinary silicon
For the 18 participants with complete urinary datasets, four
weeks of supplementation with MMST led to a marked
increase in fasting urinary silicon concentrations (mean
17.0 mg/L) compared to baseline (mean 8.5 mg/L: P =
0.008) and placebo (mean 7.8 mg/L: P = 0.007) (Figure 2B).
There was no effect of order (i.e. MMST before placebo or
placebo before MMST; data not shown).
As previously observed for dietary silicon, fasting uri-
nary silicon concentrations correlated closely with fasting
serum silicon concentrations throughout the study period
(Figure 3).
Silicon as MMST in the urine and serum samples
We used 1H-NMR to quantitate the concentration of
MMST in urine and compared that value to the total-Si
increase (as determined by ICP-OES) over and above
baseline in the paired samples. MMST was detected above
the detection limit (3 μg/L) in all 10 fasting urine samples
following supplementation with MMST (Figure 4A). Curi-
ously, MMST was also detected, albeit at much lower con-
centrations, in three of the five baseline samples (week-0)
and three of the four placebo samples (week-4) analysed
(data not shown). The concentration of MMST in the 10
fasting urine samples following MMST supplementation
accounted for only 10.3 ± 6.6% of the increase in the
total-Si excreted, consistent with significant metabolism of
the organosilicon to inorganic silicon.The serum analysis was hampered by the limits of de-
tection of 1H-NMR in this sample type (ca. 10 μg/L).
Nonetheless, in 6/9 samples, semi-quantitation could be
achieved and it was consistent with significant metabol-
ism of MMST: the concentration of Si detected as
MMST in the six fasting serum samples accounted for
50.6 ± 13.5% of the increase in total-Si (Figure 4B).
MMST was present below the detection limit in the
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Figure 3 Correlation between fasting serum and urinary silicon
levels. Correlation (r = 0.55 and P < 0.0001; n = 49) between
individual fasting urine total-Si concentrations and the
corresponding (i.e. paired) fasting serum total-Si concentrations at
baseline (solid circles) and after supplementation with MMST (open
squares) and placebo (open triangles).
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(data not shown).Safety of MMST
Serum biochemistry
There were no changes in serum biochemistry following
Si supplementation, and no effect of the sequence of
supplementation (i.e. MMST followed by placebo or pla-
cebo followed by MMST), to markers of renal function
or liver function, lipid profile, inflammation, or other
blood analytes (Additional file 1).Urine
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Figure 4 Increase in fasting serum and urinary silicon levels detected
concentration (white bars) in fasting urine (A, n=10) and fasting serum (B, n
detected in the baseline serum samples (detection limit ca. 10 μg/L), but w
detection limit 3 μg/L).Health, wellbeing and quality of life
There were no changes in the participants’ health, well-
being and quality of life following supplementation with
MMST or placebo (Additional file 1).
Discussion
Our data provide evidence that, following ingestion,
MMST [Si(OH)3CH3] is converted to orthosilicic acid
[Si(OH)4] and that supplemental use of MMST is safe.
Following four weeks of continuous supplementation
with MMST (at the maximum recommended dose of
3.5 mg Si three times per day), fasting serum and urine
Si concentrations were, on average, doubled. There appear
to be two routes of bio-distribution for dietary silicon fol-
lowing its absorption: namely, rapid urinary excretion for
the majority [22-24] and tissue loading and/or cellular me-
tabolism for a minority [24]. As a result, sustained low
dose silicon supplementation leads to a marked rise in the
body pool of silicon [25], presumably as the second, minor
pathway is increasingly loaded. The biologically important
target sites for dietary and supplemental silicon appear to
be the connective tissues, such as blood vessels [9,29],
joints, skin [30-32] and, especially, bone [2,8,11,12,26,33].
Thus the increase in fasting serum and urine Si concentra-
tions following MMST supplementation must result from
silicon that has entered the metabolic pool and not that
which is destined for immediate urinary excretion follow-
ing absorption. We were careful to avoid the latter by
using fasting serum and urine samples following a mini-
mum of a 10 h fast and previous data has shown this to be
more than adequate [10,14,24]. This marked increase in
the body pool of silicon supports the argument that
MMST is an effective silicon supplement and also explainsSerum
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as MMST. Increase of total-Si concentration (black bars) and MMST
=6) following 4-week supplementation with MMST. MMST was not
as detected in three of the baseline urine samples (21 ± 7 μg/L;
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fluence bone and blood vessels in mammalian studies
[8,9,11,12] in much the same way that dietary silicon does
[1,26,27,30-33].
Fasting serum Si levels in this study, before and after
supplementation with MMST, were variable, but baseline
levels were comparable to what we have previously ob-
served for pre-menopausal women [34]. A few baseline
samples were below the LOQ, but this is not unusual for
this population and probably reflects either the ethnic
diversity of the group with their different dietary Si ex-
posure [2,35] and/or differences in circulating hormonal
levels that could, in theory, impact upon serum and tis-
sue Si levels, although further work is required to con-
firm this [34,36]. Even with this variable Si baseline,
MMST supplementation significantly increased fasting
serum Si level above baseline. Whether this increase in
serum Si level is beneficial is not known and was not the
aim of this study. This would require a different study
design with, probably, a longer period of supplementation.
Conversely, the fact that fasting serum Si levels can be in-
creased with Si supplementation could be interpreted to
mean that normal dietary Si intake/exposure is sub-
optimal but, again, the absence of any known Si deficiency
state or symptoms makes this impossible to investigate di-
rectly. Nonetheless, as mentioned above, increased dietary
Si intake is associated with increased bone mineral density
at least in men and pre-menopausal women [26,27].
Importantly, we provide evidence for the conversion/
metabolism of MMST to OSA; namely that organosilicon
concentration in urine and serum accounted for only 10%
and ca. 50% of the increase in total-Si in the fasting urine
and serum samples, respectively. No previous data exist,
specifically, for the conversion or metabolism of MMST
to OSA. There are, however, data showing that methyl
silanes per se (Si-CH3) are broken down/converted to
silanols (Si-OH) in both the acid environment of the
stomach and systemically [15,17-19].
In designing the study, we considered how bioconver-
sion of this proposed supplemental silicon [Si(OH)3CH3]
to OSA [Si(OH)4] could be demonstrated in humans.
Stable isotopic labelling, with 29Si, was discounted due
to its relative high natural abundance (ca. 5% of all en-
dogenous Si(OH)4) and the relative insensitivity of
29Si
by NMR. Experiments with 32Si would not, these days,
allow for administration to humans due to radioactive ex-
posure and long half-life (170 years). Thus, we rationalised
that if Si loading (i.e. increased fasting serum levels) is ob-
served following sub-chronic ingestion of MMST in vol-
unteers, as observed for absorbable dietary/supplemental
silicon [1,25], then quantitation for MMST (by 1H-NMR)
together with quantitative ICP-OES for the increase in
total silicon, would allow for bio-conversion to be proven
by ‘balance’. Moreover, 1H-NMR would have detected theconversion of MMST to other organosilicons, although
MMST is the smallest organosilicon molecule (building
block) and its in vivo anabolism to form larger
organosilicon species was neither anticipated nor seen.
Interestingly, and surprisingly, MMST was also detected
in baseline urine samples and it is likely that this is due
to exposure to other organosilicon compounds that are
metabolised through this pathway (i.e. via MMST to OSA).
Notably, silicones (e.g. dimethylpolysiloxane, E900) are
added to foods such as juice and beer as an anti-foaming
agent [7,37].
Finally, the serum biochemistry and quality of life data
over the 4-week periods during which participants received
MMST would suggest that this form of silicon is safe upon
sustained dosing at supplemental levels (10.5 mg/day or
less). This finding is in accordance with reported studies of
MMST being administered orally and intravenously in
humans [8,9,11] and with its long-standing use as a supple-
ment without reported adverse events. Data in rats with the
same and higher doses of MMST, over a longer (90 day)
supplementation period, have also confirmed the safety of
this material (unpublished data).
Conclusions
In conclusion, our data provide evidence for the metab-
olism and safety of MMST at supplemental levels. The
marked increase in the body pool of silicon and evidence
of its conversion/metabolism to OSA supports the argu-
ment that MMST is an effective silicon supplement.
Intervention trials are now warranted.
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